Brennan has served as a medical director at Wyeth-Ayerst Research and GlaxoSmithKline, where he oversaw ten investigational new drug applications with the US Food and Drug Administration.
He also founded IndiPharm, a full-service clinical research organization that was later acquired by a private equity company.
READ: FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae
“Ed is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development,” CEO Raza Bokhari said. “We aim to capitalize on his expert guidance as FSD builds on our recently announced acquisition of Prismic Pharmaceuticals and continues to execute on our strategy to identify and acquire cannabinoid-based pharmaceutical R&D companies focused on FDA approved clinical trials.”
FSD Pharma is a Toronto-based producer of pharmaceutical-grade cannabis. On April 23, it announced a C$23.4 million acquisition of Prismic, a US pharmaceutical company focused on developing non-addictive drugs to combat the opioid epidemic.
Shares slipped 2.3% to C$0.22 on the CSE and 0.6% to US$0.16 on OTC markets.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel